Why the study?
Does acetylsalicylic acid, modified-release dipyridamole, or their combination prevent stroke or death in patients with prior stroke or TIA?
Does acetylsalicylic acid, modified-release dipyridamole, or their combination prevent stroke or death in patients with prior stroke or TIA?
The combination of dipyridamole and aspirin is significantly more effective than either agent alone for the secondary prevention of stroke and TIA.
Answers are grounded in this paper and cite their sources.
Combination therapy is superior for secondary prevention after stroke/TIA; confirms additive efficacy of dipyridamole plus ASA over monotherapy in RCT.
SUMMARY In 1988, an optimal antiplatelet regimen for secondary stroke prevention remained to be defined. We undertook a randomised, placebo‐controlled, double‐blind trial to investigate the safety and efficacy of low‐dose acetylsalicylic acid (ASA), modified‐release dipyridamole, and the two agents in combination. Patients with prior stroke or transient ischaemic attack (TIA) were randomised to treatment with ASA alone (50 mg daily), modified‐release dipyridamole alone (400 mg daily), the two agents in a combined formulation, or placebo. Primary endpoints were stroke, death, and stroke or death. TIA and other vascular events were secondary endpoints. Patients were followed on treatment for two years. We concluded that dipyridamole, in a modified‐release form, at a dose of 200 mg b.d. and ASA 25 mg b.d., have been shown to be equally effective in the secondary prevention of ischaemic stroke and TIA; that when co‐prescribed, the protective effects are additive, the combination being significantly more effective than each agent prescribed singly; and that low‐dose ASA does not eliminate the propensity for induced bleeding.
No takes yet. Share an insight, caveat, or question.
CD Forbes (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: